A PHASE 1, NON-RANDOMIZED, OPEN-LABEL STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF PF-07817883 IN ADULT PARTICIPANTS WITH RENAL IMPAIRMENT AND HEALTHY ADULT PARTICIPANTS WITH NORMAL RENAL FUNCTION
Latest Information Update: 07 Oct 2024
At a glance
- Drugs PF-07817883 (Primary)
- Indications COVID 2019 infections
- Focus Pharmacokinetics
- Sponsors Pfizer
- 02 Oct 2024 Planned End Date changed from 11 Nov 2025 to 28 Oct 2025.
- 02 Oct 2024 Planned primary completion date changed from 11 Nov 2025 to 28 Oct 2025.
- 02 Oct 2024 Status changed from not yet recruiting to recruiting.